Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 26 September 2006
Vol. 2006, Issue 354, p. pe35
[DOI: 10.1126/stke.3542006pe35]

PERSPECTIVES

Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin

Judah Folkman*

Children’s Hospital and Harvard Medical School, Boston, MA 02115, USA.

Abstract: Recent research shows that p53 suppresses tumor angiogenesis by transcriptionally activating the {alpha}(II) collagen prolyl-4-hydroxylase gene. This results in the extracellular release of the potent endogenous angiogenesis inhibitors endostatin and tumstatin from collagens 18 and 4, respectively. The involvement of these inhibitors elucidates a molecular mechanism. By simultaneously repressing a multitude of proangiogenic pathways and by inducing antiangiogenic pathways, a tumor suppressor protein can prevent an incipient tumor from switching to the angiogenic phenotype. Thus, p53 guards the genome from cancer by controlling the three fundamental processes that are critical for growth of a primary tumor and its metastases—tumor cell proliferation, apoptosis, and tumor angiogenesis.

*Contact information. Telephone, 617-919-2346; fax: 617-739-5891; e-mail: judah.folkman{at}childrens.harvard.edu

Citation: J. Folkman, Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin. Sci. STKE 2006, pe35 (2006).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882